Market Place
Sourcing Support
Ayala Pharma To Deregister And Suspend Reporting Obligations
09 May 2024 //
GLOBENEWSWIRE
Immunome Completes Acquisition of AL102 From Ayala
26 Mar 2024 //
BUSINESSWIRE
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
26 Mar 2024 //
GLOBENEWSWIRE
Ayala Announces Completion of Enrollment in Phase 3 Study Evaluating AL102
20 Feb 2024 //
GLOBENEWSWIRE
Immunome To Acquire AL102 From Ayala Pharmaceuticals
06 Feb 2024 //
GLOBENEWSWIRE
Immunome pays $50M for Ayala`s phase 3 desmoid tumor drug
06 Feb 2024 //
FIERCE BIOTECH
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for GIGA-564
06 Nov 2023 //
GLOBENEWSWIRE
Ayala Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
06 Nov 2023 //
GLOBENEWSWIRE
Ayala Presents Updated AL102 Results from Phase 2 Trial in Desmoid Tumors
23 Oct 2023 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
19 Oct 2023 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Ayala Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO
01 Aug 2023 //
GLOBENEWSWIRE
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
27 Jul 2023 //
GLOBENEWSWIRE
Ayala Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102
05 Jul 2023 //
GLOBENEWSWIRE
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at ASCO
05 Jun 2023 //
GLOBENEWSWIRE
Ayala Announces Updated RINGSIDE Phase 2 Results at 2023 ASCO Meeting
25 May 2023 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results
23 May 2023 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at 2023 ASCO
27 Apr 2023 //
GLOBENEWSWIRE
Ayala Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors
03 Mar 2023 //
GLOBENEWSWIRE
Ayala Reports Financial Results For the Fiscal Year Ended October 31, 2022
10 Feb 2023 //
GLOBENEWSWIRE
Advaxis and Ayala Pharmaceuticals Complete Merger
19 Jan 2023 //
BIOSPACE
Advaxis updates on phase 1 trial of ADXS-504 to treat early prostate cancer
14 Jan 2023 //
PHARMABIZ
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504
12 Jan 2023 //
GLOBENEWSWIRE
Ayala Presents Poster on AL102 in Desmoid (CTOS) 2022 Annual Meeting
17 Nov 2022 //
GLOBENEWSWIRE
Ayala Pharma Announces First Patient Dosed AL102 in Ph3 Segment RINGSIDE Trial
16 Nov 2022 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Reports 3Q FYR and Provides Corporate Update
04 Nov 2022 //
GLOBENEWSWIRE
Ayala and Advaxis fuse together to pool funds for lead programs
19 Oct 2022 //
FIERCEBIOTECH
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
29 Sep 2022 //
GLOBENEWSWIRE
Ayala Announces Fast Track Designation Granted by US FDA for AL102
27 Sep 2022 //
GLOBENEWSWIRE
Ayala Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial
12 Sep 2022 //
GLOBENEWSWIRE
Ayala Selected to Present Efficacy Data on AL102 in Desmoid Tumors at ESMO
24 Aug 2022 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Reports Second Quarter 2022
15 Aug 2022 //
GLOBENEWSWIRE
Ayala Announces Interim Data from Part A of PII/III RINGSIDE Trial of AL102
05 Jul 2022 //
GLOBENEWSWIRE
Advaxis Updates on PI Trial of ADXS-504 for Early Prostate Cancer
29 Jun 2022 //
GLOBENEWSWIRE
Ayala Pharma Announces Data on AL101 in ACC at 2022 ASCO Annual Meeting
06 Jun 2022 //
GLOBENEWSWIRE
Advaxis, Inc. Announces 1-for-80 Reverse Stock Split
03 Jun 2022 //
GLOBENEWSWIRE
Ayala Pharma to Present at the 2022 Jefferies Global Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Advaxis to Present Updated Data from Ongoing PI/II Trial of ADXS-503
26 May 2022 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Advaxis to Present at the ASCO 2022 Annual Meeting
27 Apr 2022 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 ASCO
27 Apr 2022 //
GLOBENEWSWIRE
Advaxis Announces Publication of ADXS-PSA Data in The Oncologist
08 Apr 2022 //
GLOBENEWSWIRE
Ayala Pharma Reports Full-Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Advaxis Reports Q1 Ended January 31, 2022 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Ayala Pharma to Present at the 32nd Annual Oppenheimer Conference
09 Mar 2022 //
GLOBENEWSWIRE
Ayala Pharma Completes Enrollment in Part A of RINGSIDE Phase 2/3 Study of AL102
23 Feb 2022 //
GLOBENEWSWIRE
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock
28 Jan 2022 //
GLOBENEWSWIRE
Advaxis Presents Updated Data from Phase 1/2 Trial of ADXS-503 in NSCLC
11 Jan 2022 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Announces Key Business Objectives for 2022
04 Jan 2022 //
BIOSPACE
Advaxis Announces Acceptance for Trading on the OTCQX
22 Dec 2021 //
GLOBENEWSWIRE
Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
11 Nov 2021 //
GLOBENEWSWIRE
Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference
10 Nov 2021 //
GLOBENEWSWIRE
ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight
03 Nov 2021 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity AL101
23 Sep 2021 //
GLOBENEWSWIRE
Ayala Pharma Presents Preliminary Data from Ongoing Phase 2 ACCURACY Trial
16 Sep 2021 //
GLOBENEWSWIRE
Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results
10 Sep 2021 //
GLOBENEWSWIRE
Ayala Pharmaceuticals to Present Clinical Data from Ongoing trials at ESMO 2021
01 Sep 2021 //
GLOBENEWSWIRE
Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results
13 Aug 2021 //
GLOBENEWS WIRE
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504
15 Jul 2021 //
GLOBE NEWSWIRE
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504
15 Jul 2021 //
GLOBE NEWSWIRE
